19 filings · most recent first
ACLX 8-K Filings
Gilead To Acquire Arcellx In 78 Billion Deal To Accelerate Anitocel Development
Arcellx Announces Positive Data From Phase 2 Immagine1 Study For Rrmm Treatment
Arcellx Reports Third Quarter 2025 Financial Results
Arcellx Inc Annual Meeting Results Directors Elected Compensation Approved And
Arcellx Announces Positive Phase 2 Data For Rrmm Therapy
Arcellx Reports First Quarter 2025 Financial Results And Business Highlights
Arcellx Appoints New Board Members And Announces Departure
Arcellx Reports Positive Financial Results For Fiscal Year 2024
Arcellx Hosts Investor Event Highlighting Positive Clinical Trial Results For
Arcellx Announces Positive Phase 2 Data For Rrmm Therapy At Ash
Arcellx Reports Third Quarter 2024 Financial Results And Highlights Clinical
Arcellx To Present Clinical Data For Relapsed Or Refractory Multiple Myeloma At
Arcellx Reports Second Quarter 2024 Financial Results And Business Updates
Arcellx Inc Announces Results Of Annual Meeting Of Stockholders
Arcellx Reports First Quarter 2024 Financial Results
Arcellx Inc Announces Change In Independent Registered Public Accounting Firm
Arcellx Inc Announces Lease Termination And Headquarters Relocation
Arcellx Announces Second Quarter 2025 Financial Results And Business Highlights
Arcellx Reports Q4 2023 Financial Results And Business Highlights